





Accepted: 21 January 2019 (In Press) 
 
The development and first validation of a Patient Reported Experience Measure in 
Chronic Obstructive Pulmonary Disease (PREM-C9)  
 
Matthew Hodson,1 C Michael Roberts,2 Sharon Andrew,3 Laura Graham,1 
Paul W Jones,4 Janelle Yorke5 
1. ACERS, Homerton University Hospital NHS Foundation Trust, 
London, UK 
2. Barts and The London School of Medicine and Dentistry, London, 
UK 
3. Department of Nursing & Midwifery, Victoria University, Melbourne, 
Victoria, Australia  
4. St Georges, University of London, London, UK 
5. School of Nursing, Midwifery & Social Work, University of 
Manchester, Manchester, UK 
 
KEY MESSAGES  
What is the key question  
Living with COPD impacts greatly on a person’s everyday life; including experience of living 
with COPD and as a recipient of healthcare. No currently available instrument captures this 
experience.  
What is the bottom line 
We have developed and validated a COPD Patient Reported Experience Measure (PREM-
C9). A simple and easy to use 9-item unidimensional measure designed to quantify the 
experience of people living with COPD.    
Why read on?  
The article describes the development and validation of the PREM-C9 which will enable 
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The development and first validation of a Patient Reported Experience Measure in 
Chronic Obstructive Pulmonary Disease (PREM-C9) 
Introduction  
The drive to improve the quality of care for patients requires robust instruments to  capture  
patients’ perceptions of the health care that they receive. The experience of patients living 
with chronic obstructive pulmonary disease (COPD) and their views on the quality of 
healthcare they receive is not captured in currently available Patient Reported Outcome 
Measures (PROM)1. A new era of measures - Patient Reported Experience Measures 
(PREM) – is emerging. PREM’s assess patient experiences as opposed to outcomes (such 
as symptoms and quality of life) per se2. PREMs are often used as a benchmark for care 
experience and the experience of living with a disease that complements information 
obtained with PROMs. Here, we present the development and validation of a COPD specific 
PREM. 
Methods  
Study 1: A 38-item list, extracted from our previous qualitative work3, the COPD 
Assessment Test (CAT)4 and Hospital Anxiety and Depression Scale (HADS)5 were 
administered to patients with COPD6. Hierarchical item reduction and Rasch analysis were 
applied to our 38 items to identify those with the best measurement properties and potential 
for inclusion7. This iterative process continued until a final item-set that met the Rasch 
unidimensional measurement model requirements was achieved8. Test-retest reliability was 
assessed in patients who repeated the item-list one-week later and reported that their 
general health was ‘about the same’. Concurrent validity was assessed using correlations 
between the final item-list (PREM-C9), CAT and HADS (see online supplement).  
Study 2: Further concurrent validity of PREM-C9 with the CAT and HAD, and its change 
scores pre and post pulmonary rehabilitation (PR) were tested in a sub-study (see online 
supplement).  
Data Analysis   
Items were flagged for removal due to floor/ceiling effects (>40%), age bias (Pearson’s 
correlation), gender bias (independent t-test), item-item correlation (>0.7), and missing 
responses (>15%). Fit to the Rasch model was determined by a non-significant chi-
square statistic (p>0.05) and Person Separation Index (PSI) (>0.7). Test-retest reliability 
was assessed using the Intra-class correlation coefficient (values >0.7). Construct validity 
was assessed in both studies using correlations (Pearson's r) between PREM-C9, CAT and 
HAD. Statistical significance was set at p <0.05. In study 2, PREM scores pre and post PR 







Study 1: PREM development and preliminary validation  
In total, 174 patients completed the questionnaire pack (Mean age 71 years, SD 9; Female 
52%; Mean FEV1 59%, SD 21.9) (Table 2 online supplement). Participants were recruited 
via British Lung Foundation Breathe Easy Groups (n=88, 51%) and hospital and community 
pulmonary services (n=86, 49%). 40 people declined to participate in the study. Reasons 
included the time to complete the questions, feeling too unwell and language.   
Item reduction 
Twenty-two of the 38 items were removed in hierarchical reduction: age bias (n=6), gender 
bias (n=1), missing data (n=6), floor effect (n=12), item-to-item correlation (n=4), and three 
items due to expert opinion (Table 1 online supplement). The remaining 13 items underwent 
Rasch analysis. Four items were removed due to poor fit to the Rasch unidimensional 
model. The final 9-item solution (PREM-C9) demonstrated good fit to Rasch (xp=0.33; PSI = 
0.75) and good distribution of item scores (logit range: -0.1 to +0.2) (Figure 1 and Figure 2). 
Each PREM-C9 item is scored 0 (good experience) to 5 (bad experience); total score ranges 
from 0 to 45 (Table 3 online supplement). PREM-C9 scores moderately correlated with CAT 
(r =0.42), HAD-anxiety (r =0.30) and HAD-depression (r =0.41) (p<0.05).  
Test-retest reliability was assessed in 88 (49%) participants and was acceptable (ICC=0.7).   
Study 2: PREM validation and change scores 
36 patients with confirmed COPD (Mean age 65 years, SD 10.97; Male 61%; Mean FEV1 
53.4%, SD:19.4) completed questionnaires pre and post PR. PREM-C9 demonstrated very 
similar correlations to those seen in Study 1: CAT (r=0.48) HAD-Anxiety (r=0.44) and HAD-
Depression (r=0.46). A significant difference in PREM-C9 scores pre and post PR was found 
(20.088.43 and 14.7210.59, respectively; mean change 5.369.70, 95% CI: 2.08 to 8.64, 
p=0.002), indicating improved experience.  
Discussion 
We report the development and validation of the first COPD PREM. The PREM-C9 offers a 
new approach by capturing patient experience and their interactions with healthcare systems 
and clinicians in three main areas of COPD: ‘usual care in COPD’ (items 1-3); ‘my everyday 
day life with COPD (items 4-7); and ‘self-management and exacerbations’ (items 8-9). These 
sections draw upon important patient-centred aspects of COPD.  
PREM-C9 demonstrated good fit to the Rasch model confirming that its items relate to the 
same underlying structure – patient experience; enabling simple item summation to obtain 






other PROM’s suggesting that the PREM captures a related but somewhat different patient 
perspective.   
The focus on ensuring that patients remain at the heart of healthcare and reporting patient 
experience is becoming an essential part of quality improvement. Evaluation of healthcare 
experience is continuously evolving with the patient perspective increasingly sought9. This 
approach differs from the measurement of symptoms and quality of life. Current satisfaction 
surveys are also limited as they are normally generic and loosely constructed1. Assessment 
using PROMS is important but they do not capture the experiential views of patients1.  
This short instrument should complement the range of instruments currently used within the 
COPD population when used alongside clinical audit and quality improvement strategies 10. 
Measuring and benchmarking patients experience in a systematic way pre and post 
healthcare intervention may be a powerful way to demonstrate quality improvement and 
outcomes for healthcare professionals and patients.  
Our study does have limitations. Patients recruited indicated they attended Breathe Easy 
specifically for their COPD condition as advised by medical/nurse practitioner and had 
spirometry at time of recruitment but we did not confirm this through accessing medical 
records. We conducted questionnaires in English only and results may not be applicable 
linguistically across a diverse patient group. Patients who did not have a good knowledge of 
English declined to participate as subjects from which the PREM was derived.  
 
Conclusions  
We have summarised the development and preliminary validation of the first published 
PREM in COPD (PREM-C9). The instrument was designed to present what patients 
consider is important to them in relation to their care. We suggest this instrument should be 
used in routine practice to aid clinicians to understand the patient perspective and to form 
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The development and first validation of a Patient Reported Experience Measure in 
Chronic Obstructive Pulmonary Disease (PREM-C9: Online Supplement  
 
Detailed Methods  
Stage 1  
Participants with COPD were recruited from a number of NHS secondary and integrated 
care organisations which included pulmonary rehabilitation, respiratory clinics and wards. 
Also British Lung Foundation Breathe Easy groups (self supported groups for people 
affected by lung disease) from various locations across England and the Channel Islands.  
 
Inclusion criteria included:  
 A confirmed diagnosis of COPD (mild to very severe COPD (FEV1 <100% with 
symptoms); 
 Able to consent and sign a consent form; 
 Able to follow written and verbal instructions in English (Due to the availability of 
advocacy services, those whose first language is not English and who are unable to 
read or understand verbal English will not be able to participate in the study, unless a 
family member is available to support and translate during the study period); 
Exclusion criteria included:  
 Other respiratory conditions such as Asthma/pulmonary fibrosis; 
 Who are nearing end of life; 
 Had significant other co-morbidities such as severe heart failure. 
 
Stage 2  
Participants with COPD were recruited from a singular NHS integrated care organisation 
which had a number of pulmonary rehabilitation sites across the hospital and community.  
Inclusion criteria included:  
 A confirmed diagnosis of COPD (mild to very severe COPD (FEV1 <100% with 
symptoms); 
 Able to consent and sign a consent form 
 Completed Pulmonary Rehabilitation by end of May 2016 
 Completed a full PR pre-data set 
 Met the City and Hackney Pulmonary Rehabilitation inclusion criteria 
Exclusion criteria included:  
 Other respiratory conditions such as Asthma/pulmonary fibrosis 
 Required full assistance to complete questionnaires i.e.: prompting 






 Incomplete set of post-data  
Date Collection  
Stage 1  
A healthcare professional conducted daily screening (Monday to Friday) of all patients 
admitted to the hospital with an acute exacerbation of COPD. They also conducted 
screening of outpatients attending pulmonary rehabilitation clinics (time and days varied 
dependent on activity), as well as the hospital PR group who were not inpatients at the time 
of recruitment and community COPD patients and PR groups. The healthcare professional 
approached eligible patients and their families prior to discharge, or earlier, dependent on 
how unwell the patient was. They described the study and invited the potential participant to 
take part in the study. If, during screening, the patient did not fit the inclusion criteria the 
patient was not entered on to the study. The healthcare professional administered and 
signed a consent form along with the participant. Patients were informed to read each 
statement of the question (Table one) and rate their answer which they felt reflected their 
own experience over the last year from a good experience (0) to a poor experience (5). Pack 
A included a COPD PREM instrument, CAT & HAD questionnaires which was given to the 
consenting patient.  
 
Participants then had three options to do the following:  
a. take Pack A home with them and return the questionnaires in  
a stamped address envelope to the participating NHS organisation, or, where 
it was a Breathe Easy Group, send all instruments back to the 
Chief Investigator of the study; 
b. take Pack A home and return the completed pack to the pulmonary 
rehabilitation or COPD clinic from where they were recruited; 
c. complete Pack A ‘there and then’ (preferred option). 
 
Pack B consisting of a COPD-PREM instrument and a global rate of change questionnaire 
was also completed and sent back to the Chief Investigator one week later in the provided 
SAE. 
Throughout the process, regardless of which option of completing the instrument packs, the 
consent, spirometry and demographic data where completed at the time of recruitment. All 
instruments were labelled with the participants’ unique letter and number code. All patients 
recruited from the Breathe Easy group followed the same process named above.   






The NHS Integrated care organisation pulmonary rehabilitation service database was 
searched for patient data meeting the study inclusion criteria and who completed pulmonary 
rehabilitation between June 2015 and May 2016.  All patient data meeting the inclusion 
criteria and within the study period was extracted from the database for the purpose of this 
study. Every patient referred to the CHPR service completed an initial assessment and if no 
contraindication to exercise was identified, the patient enrolled onto the PR programme of 
choice.  The outcomes completed pre and post PR were: 
The primary outcome measure:  
 PREM-C9 
The secondary outcome measures:  
 COPD Assessment Test (CAT)  
 Hospital Anxiety Depression Score (HADS) 
For participants who were unable to complete the questionnaires independently due to 
literacy or language barriers, assistance was provided with read only assistance from either 
the CHPR staff or an advocate, all answers however had to be the participants alone.  
When a patient completed 16 sessions of PR, the measured outcomes were repeated at a 
final assessment.  
Data Analysis  
Stage 1 
The response rate for questionnaire completion was 81% (n = 174). Those who declined to 
participate in the study cited reasons such as ‘the time to complete the questions’, ‘feeling 
unwell’ and ‘language (comprehension)’. All statistical analyses were conducted using SPSS 
Statistics for Windows, Version 20.0 or RUMM2030. Rasch is recommended by the FDA 
and enables development of a concise scale with a minimal number of items needed to 
capture the underlying trait 'experience' – without jeopardising its scaling properties.  
This study adopted a test-retest questionnaire development design. Demographics including 
age, gender, FEV1%, MRC and the results of the questionnaires and preliminary COPD-
PREM were recorded (Table 2) and entered into SPSS initially. A formal approach to the first 
stage of item reduction was used following a series of different statistical approaches and 
following a traditional psychometric theory1. A number of statistical tests were undertaken to 







Following the hierarchical item reduction a pool of items remained. Items were identified for 
removal based on a combination of panel review, similarity with other items, grammatical 
challenges, and statistical fit. The expert panel consisted of respiratory physicians and 
nurses as well as question design expertise. The items removed at this stage were 
considered to have borderline fit only in relation to these criteria and were removed in favour 
of items with better overall fit to the item-list as a whole. 
 
The remaining items went through a series of comprehensive tests to explore the data and 
to understand the current fit to the model. With the overall aim to test how well the observed 
data fit the expectations of the measurement model.  
Stage 2   
Statistical analysis was performed using IBM Statistical Package for Social Sciences (SPSS) 
Version 22.  The data in this study was presented in either a table or a side by side bar 
chart.  
Using descriptive analysis, all patient baseline data (Table 2)  was analysed for normality via 
a histogram plot.  Where normality was assumed the data was summarised as Mean and 
Standard Deviation (M  SD); if the data were asymmetrical, via Median and range or 
percentiles. All categorical data was summarised as percentages2.   
The data from the primary and secondary measured outcomes were analysed for normality, 
and if assumed a paired t-test and 95% confidence interval (95% CI) was used to compare 
the difference in pre and post PR scores. For all statistical analysis, significance was set as 
a p value <0.05. If normality was not assumed the relevant non parametric test was used.  
Correlation between the primary and secondary outcomes was analysed using a Pearson 
product-moment correlation co-efficient (r=)2 test, where normality was assumed.  If 
normality was not assumed, a Spearman’s Rank Order correlation test for non-parametric 
data was performed (rho=) instead.  
Between groups, analysis was performed to measure the impact of either gender, age, 
smoking status, MRC grade and disease severity on the primary outcome scores. The test 
performed depended upon the number in each group. If there were two groups and 
normality assumed, an independent t-test or a Mann Whitney U-test when the data was 
asymmetrical was performed. For more than two groups, the relevant ANOVA test was used 










The instrument was designed to present what patients consider is important to them in 
relation to their care. We envisage the instrument being used by a nurse/therapy led clinics 
and Pulmonary Rehabilitation to assist dialogue interactions with patients to understand the 








Table 1: Reason for item removal stage 1  
Q 







      Other 
Correlation    
1 I am not shocked by my COPD diagnosis 
   
Expert  
2 I have come to terms with my diagnosis of 
COPD    
Rasch 
 
3 I have given up smoking and I am confident 





















7 I am confident that my GP will listen to my 
point of view**    
 
 





9 I am happy with the length of time to see GP 
   
Rasch 
 
10 I really enjoyed pulmonary rehabilitation X 
  
 Q11 
11 I found pulmonary rehabilitation useful X X 
 
 Q11 
12 I understand my condition and this helps me to 




















16 I am confused about how to use my COPD 
inhalers    
Rasch 
 






18 I don’t find going to a hospital outpatient clinic 
frustrating    
  
Q20 






20 I have accepted the limitations to my lifestyle 
caused by COPD**    
 
 
21 I feel that I have good support from others** 
   
 
 
22 Overall I am satisfied with my life 
   
Rasch  
 
23 I am not depressed 
   
Expert  
 












26 I feel that I am in control of my condition** 
   
 
 



















































31 I keep going and try to enjoy my life 
 
X X  
 
32 I am confident in a ‘flare up’ I have quick 
access to treatment**    
 
 




34 I am not worried about the care I will get with 
'flare-up'**    
 
 




36 I am not frightened of being breathless when I 




37 I am not frightened to go to sleep when I am 
having a ‘flare up’ of my COPD    
Expert  
 
38  I try not to panic when I have a ‘flare up’ as it 
















 N = 174 N = 36  
Age, years (Mean ±SD) 71± 9.1 65.6 ±10.97 
Gender   
 Male (%) 83 (48%) 22 (61.1%) 
 Female (%) 91 (52%) 14 (38.9%) 
Smoking status, number   
 Active smokers 20 (12%) 11 (30.6%) 
 Ex-smokers 125 (72%) 22 (61.1%) 
 Not disclosed/Non  29 (16%) 3 (8.3%) 
Spirometry  
FEV1 (% predicted) 
(Mean ±SD) 
59±21.9 53.4±19.39 
FEV1 % /FVC (Ratio)  
(Mean ±SD) 
50±20.4 56±14.0 
NICE classification*† % (n)  
 Mild 23 (13) 19.4 (7) 
 Moderate 46 (26) 2.8 (1) 
 Severe 50 (29) 30.6 (11) 
 Very Severe 26 (17) 44.4 (16)  
Outcome measures   
Medical Research Council (MRC)  
(Mean ±SD) 
3.4±1.0 3.17±0.7 




     23.5±7.7 
 
Anxiety Score  
(Mean ±SD) 
7.6±4.1 8.1±5.1 
Depression Score  
(Mean ±SD) 
6.1±3.9 7.4±3.9 
Data shown represented mean ± SD unless otherwise indicated 
FEV1: Forced expired volume in one second; FVC: Forced vital capacity 
*NICE (2010) Classification  
† 







Table 3: Final nine PREM C-9 Items   
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Q Low Scoring Question (0)  High scoring Question (5) 
1 
I am confident that my GP will listen to 
my point of view 
 
I am concerned that my GP won’t 
listen to my point of view 
2 
I have enough information about my 
condition 
 
I am frustrated by my lack of 
information about my condition 
3 
I understand how my COPD treatments 
work 
 
I am confused about how my COPD 
treatments work 
4 
I have accepted the limitations to my 
lifestyle caused by COPD 
 
I am frustrated and unhappy by the 
limitations to my lifestyle caused by 
COPD 
5 
I feel that I have good support from 
others like my family, friends, 
neighbours or carers 
 
I feel that I don’t have any support 
from others like friends, family, 
neighbours or carers 
6 
I feel that I am in control of my 
condition 
 
I feel that I don’t have any control over 
my condition 
7 I am happy to talk about the future  
Talking about the future makes me 
feel depressed 
8 
I am confident in a ‘flare up’ I have 
quick access to treatment e.g. a rescue 
pack or access to my GP 
 
I am worried that in a ‘flare up’ I don’t 
have quick access to treatment e.g.  
a rescue pack or access to my GP 
9 
I am not worried about the care I will 
get from health professionals when I 
get a ‘flare-up’ 
 
I worry about the care I will get from 
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